By

With rheumatism, and certainly with chronic variants such as juvenile rheumatism, people often look for ways to better support both the body and the mental strain. In that broader picture, the question sometimes arises whether supplements such as coenzyme Q10 (CoQ10) can be useful as preparation for a psilocybin session. The idea behind this is understandable: if your body is better “in balance,” an intense experience might also unfold differently.

In this article, we objectively outline what is known about CoQ10 for rheumatism, what psilocybin can do on a biochemical and psychological level, and where the limits lie regarding what can and cannot be concluded based on current research. Where we discuss hypotheses, we state this explicitly.

What is CoQ10 and why is it mentioned for rheumatism?

CoQ10 is a naturally occurring substance involved in energy production in cells. It plays a role in the mitochondria (the “powerhouses” of the cell) and also possesses antioxidant properties. Antioxidants are often discussed in relation to oxidative stress, a process associated with inflammation and tissue damage, among other things.

Inflammatory processes play an important role in rheumatic diseases. Some studies also examine the balance between oxidative stress and antioxidant protection. From that perspective, it is logical that CoQ10 is receiving attention as a potential supportive factor alongside regular care. However, it is important to note that this is not a substitute for medical treatment, and effects can vary significantly from person to person.

The source article refers to research on juvenile idiopathic arthritis (JIA) in which CoQ10 was investigated as an adjunct. Among other things, changes were observed in disease activity and certain inflammatory markers. That sounds promising, but it remains essential to consider the size of the study, the studied population (for example, children versus adults), and whether the results are replicable in larger, independent studies.

What does psilocybin do, apart from the “mental” effect?

Psilocybin is the active ingredient in magic truffles and psilocybin mushrooms, among others. It is primarily known for altered consciousness, emotional deepening, and sometimes intense sensory experiences. In research and theory, psilocybin is also linked to biological processes, such as influencing the serotonin system (particularly via the 5-HT2A receptor).

In addition, scientific literature explores whether psychedelics may indirectly influence stress regulation, inflammatory pathways, and neuroplasticity. Mechanisms are mentioned, for example, such as changes in specific signaling pathways and possible effects on inflammation-related messenger substances. At the same time, it holds true that the fact that a mechanism is biologically plausible does not necessarily mean that it is clinically relevant for rheumatism, or that the effect is predictable and repeatable.

The psychological aspect is also important and should not be simplified. Chronic pain and chronic illness can be accompanied by stress, anxiety, depression, or a constant state of alarm of the nervous system. Some people describe that a psilocybin session changes their relationship with pain, tension, or the perception of illness. These are anecdotal accounts and not proof of a medical effect on the underlying condition.

A psilocybin session and rheumatism: what is realistic to expect?

If someone has rheumatism and is considering a psilocybin session, it is important to maintain realistic expectations. A session may potentially help with themes such as coping, stress, quality of life, emotional processing, and finding meaning. These are areas with which psychedelics are more frequently associated in a broader sense, including in research settings.

However, it is one thing to claim that psilocybin “inhibits inflammation” or reduces rheumatism. Such claims require controlled clinical research, specifically in rheumatic conditions, with clear outcome measures. Such data are currently limited or lacking. Case reports and isolated experiences may be interesting as a starting point for research, but they do not constitute a basis for establishing effectiveness.

From a practical perspective, it is also relevant that a session can be physically intense. Consider tension, nausea, emotional activation, or an altered perception of sensations. For people with pain complaints, this can sometimes be experienced as burdensome, although this varies greatly depending on the person and setting.

CoQ10 as preparation: a plausible hypothesis, not a proven protocol

The core question is: can CoQ10 be “useful” in preparation for a psilocybin session for rheumatism? At present, this can only be approached as a hypothesis. The idea is that CoQ10 may contribute to a more favorable starting position by supporting energy metabolism and oxidative balance, while psilocybin works via other routes, including stress processing and neuropsychological flexibility.

In theory, a better physical foundation could help to get through a session more comfortably. However, that is not a proven chain. It is also unclear whether any changes in oxidative stress or inflammatory markers due to CoQ10 translate into noticeable differences during or after a session, let alone specifically in the case of rheumatism.

Moreover, there are important limitations:

First, there is no direct research into the combination of CoQ10 plus psilocybin in rheumatism. Second, the relevant CoQ10 research that is often cited cannot be automatically translated one-to-one to other groups or contexts. Third, potential interactions with medication for rheumatism have not been sufficiently investigated in combination with psychedelics. This means that caution and a critical attitude remain necessary.

Safety and harm reduction: why context is important

When it comes to a guided psilocybin session, context is essential. Set (mental state), setting (environment), guidance, preparation, and integration have a significant influence on how someone experiences the session. This is especially true when chronic pain or a medical condition is involved.

In the Netherlands, it is important to state factually that supervised MDMA sessions can currently only take place within scientific research or in practice via harm reduction. The same applies to psilocybin sessions: the legal and practical context can vary depending on the form and setting. What we can do here is discuss general information and harm reduction principles, not provide individual medical or legal advice.

Anyone considering using supplements in the run-up to a session would be wise to be extra vigilant regarding: existing medication, underlying conditions, susceptibility to side effects, and the risk of “stacking” interventions without a clear overview. Even with supplements, “natural” does not equate to “risk-free,” especially when used in combination.

How can you approach this subject responsibly?

A responsible approach begins with separating three things: what has been demonstrated in research, what is plausible based on mechanisms, and what people experience personally. The source article discusses these layers and can be read via CoQ10 and psilocybin for rheumatism: what does the research say and could a combination be beneficial?. That helps maintain the nuance: interesting as a line of thought, but not (yet) a fixed roadmap.

If you are primarily looking for guidance, preparation, and integration surrounding a session, it is often more sensible to consider the quality of the setting and the guidance than to focus on a single supplement as the “key.” Practical choices such as screening, intention, preparation, and aftercare can play a larger role in the experience than people expect beforehand.

Anyone wishing to explore whether a guided session might be appropriate in a harm-reduction context can orient themselves via the page. Sign up for MDMA session. Even if your primary interest lies in psilocybin, an intake interview can help clarify expectations, safety, and prerequisites.

Conclusion

Using CoQ10 as preparation for a psilocybin session for rheumatism is an idea that may sound biologically plausible, because CoQ10 is linked to energy metabolism and oxidative balance, and psilocybin to stress regulation and broader neurobiological processes. At the same time, direct research into this combination in rheumatism is lacking, making it nothing more than a hypothesis.

Those engaged in this would do well to continue distinguishing between research, assumptions, and anecdotal evidence, and to prioritize safety and guidance. A session can be meaningful for experience and coping, but it is not a guaranteed treatment for rheumatism.